Protagonist Therapeutics (PTGX) Net Income towards Common Stockholders (2015 - 2026)

Protagonist Therapeutics has disclosed Net Income towards Common Stockholders across 12 years of filings, most recently posting $3.8 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $3.8 million, up 132.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$114.7 million (up 48.59% YoY), and the FY2025 annual result was -$130.1 million, down 3005.44% from the prior year.
• Net Income towards Common Stockholders came in at $3.8 million for Q1 2026 at Protagonist Therapeutics, up from -$44.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $207.4 million in Q1 2024 to a low of -$147.7 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$33.7 million (2023), against an average of -$19.8 million.
• Peak annual rise in Net Income towards Common Stockholders reached 714.87% in 2024, while the deepest fall reached 640.35% in 2024.
• Protagonist Therapeutics' Net Income towards Common Stockholders stood at -$34.3 million in 2022, then soared by 179.78% to $27.3 million in 2023, then plunged by 640.35% to -$147.7 million in 2024, then soared by 69.95% to -$44.4 million in 2025, then soared by 108.52% to $3.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $3.8 million (Q1 2026), -$44.4 million (Q4 2025), and -$39.3 million (Q3 2025), per Business Quant data.